STAT3 and gastric carcinoma: Prior research has demonstrated that inhibiting activated STAT3 can stop chemotherapy-induced resistance within human gastric carcinoma cells [50, 51], and that focusing on stomach epithelial STAT3 specifically may be therapeutically efficient at hindering the development of gastric cancer [52].